ONCOLYTICS BIOTECH INC (ONCY) Stock Price, Quote, News and Overview
NASDAQ:ONCY - Nasdaq - CA6823108759 - Common Stock - Currency: USD
ONCY Quote, Performance and Key Statistics
ONCOLYTICS BIOTECH INC
NASDAQ:ONCY (1/23/2025, 9:22:48 PM)
Premarket: 0.8003 -0.01 (-1.12%)0.8094
-0.07 (-8.02%)
The current stock price of ONCY is 0.8094 USD. In the past month the price decreased by -2.6%. In the past year, price decreased by -33.66%.
ONCY Latest News, Press Releases and Analysis
In today's session, these stocks are experiencing unusual volume.
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
/PRNewswire/ -- USA News Group News Commentary – Big developments are expected this week at the 2025 ASCO Gastrointestinal Cancers Symposium, running January...
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NASDAQ:GILD),(NYSE:BMY) EQNX::TICKER_END
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium
Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Pelareorep-based therapy demonstrates strong safety profile with new chemotherapy regimen in pancreatic cancer patients SAN DIEGO, CA and CALGARY, AB – January 22, 2025 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in […]
Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today provided...
ONCY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.88 | 301.60B | ||
| AMGN | AMGEN INC | 14.46 | 149.37B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.80B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 862.22 | 113.24B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.29 | 76.33B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.54B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.43B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.66B | ||
| NTRA | NATERA INC | N/A | 22.68B | ||
| BIIB | BIOGEN INC | 8.8 | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.18B |
Related stock screener links
About ONCY
Company Profile
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. The firm is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Company Info
ONCOLYTICS BIOTECH INC
804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7
Calgary ALBERTA T2N 1X7 CA
CEO: Matthew C. Coffey
Employees: 29
Company Website: https://www.oncolyticsbiotech.com/
Investor Relations: http://www.oncolyticsbiotech.com/investor-centre/investor-overview/
Phone: 14036707377
ONCY FAQ
What is the stock price of ONCY?
The current stock price of ONCY is 0.8094 USD.
What is the symbol for ONCOLYTICS BIOTECH INC stock?
The exchange symbol of ONCOLYTICS BIOTECH INC is ONCY and it is listed on the Nasdaq exchange.
On which exchange is ONCY stock listed?
ONCY stock is listed on the Nasdaq exchange.
Is ONCY a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ONCY, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ONCY.
Does ONCY stock pay dividends?
ONCY does not pay a dividend.
What is the Short Interest ratio of ONCY stock?
The outstanding short interest for ONCY is 3.51% of its float.
ONCY Technical Analysis
ONCY Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ONCY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to ONCY. The Buy consensus is the average rating of analysts ratings from 11 analysts.